Progress on MYCT1 in malignant tumors and immunotherapy
MYCT1(MYC Target 1)is a novel gene first cloned in laryngeal cancer in 2003,showing downregulation in laryngeal cancer and exerting tumor-suppressive functions.Subsequent studies have shown that MYCT1 is not only essential for maintaining normal cellular life activities in the body,but also for participating in tumor cell proliferation,differentiation,migration,apoptosis,and epithelial-mesenchymal transition through its abnormal regulation,correlating with tumor prognosis.MYCT1 plays different roles in various malignant tumors,displaying either oncogenic or tumor-suppressive functions.Recent studies have shown that MYCT1 is involved in regulating the interaction between tumor blood vessels and immune cells,contributing to tumor immunity.MYCT1 as a potential angiogenic gene participates in regulating the growth of tumor blood vessels,thereby affecting tumor metastasis and invasion,moreover,MYCT1 can affect the immune escape ability of tumor cells to immune cells.The above studies indicate that MYCT1 may become a new target for the treatment of malignant tumors and immunotherapy,providing new insights into tumor therapy.
万方数据
维普
